Literature DB >> 9425999

Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries.

T Okamura1, M Toda, K Ayajiki, N Toda.   

Abstract

Arginine vasopressin (AVP) produced relaxations at low concentrations (10[-11] and 10[-10] M) and contractions at higher concentrations in canine ciliary arterial strips with endothelium, partially contracted with prostglandin F2alpha. The AVP-induced relaxation was abolished or reversed to a contraction by removal of the endothelium or treatment with NG-nitro-L-arginine. The effect of this antagonist was reversed by L-arginine. The relaxant response was inhibited dose-dependently by SR49059 (10[-10]-10[-9] M), [Pmp1,Tyr(Me)2]-Arg8-vasopressin (PMP-AVP) (10[-10]-10[-9] M), V1 receptor antagonists, and OPC31260 (3 x 10[-8] M), a reported V2 receptor antagonist, but not by OPC21268 (10[-7]-10[-6] M), a reported V1 antagonist. In the endothelium-denuded strips, the AVP-induced contraction was attenuated by SR49059, PMP-AVP and OPC31260, but not by OPC21268. It is concluded that AVP in low concentrations elicits intense relaxation of canine ciliary arteries, possibly due to nitric oxide synthesized in association with activation of the endothelial V1 receptor subtype. AVP-induced contractions appear to be mediated also by the V1 receptor in smooth muscle. Antagonistic selectivities of the OPC compounds to vasopressin receptor subtypes could not be seen in this particular material.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9425999     DOI: 10.1159/000159257

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  10 in total

1.  Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial.

Authors:  François Lauzier; Bruno Lévy; Patrice Lamarre; Olivier Lesur
Journal:  Intensive Care Med       Date:  2006-09-22       Impact factor: 17.440

2.  The effect of vasopressin on choroidal blood flow, intraocular pressure, and orbital venous pressure in rabbits.

Authors:  Barbara Bogner; Birgit Tockner; Christian Runge; Clemens Strohmaier; Andrea Trost; Manuela Branka; Wolfgang Radner; Jeffrey W Kiel; Falk Schroedl; Herbert A Reitsamer
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-09       Impact factor: 4.799

3.  The effect of vasopressin on ciliary blood flow and aqueous flow.

Authors:  Barbara Bogner; Christian Runge; Clemens Strohmaier; Andrea Trost; Birgit Tockner; Jeffrey W Kiel; Falk Schroedl; Herbert A Reitsamer
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-21       Impact factor: 4.799

Review 4.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

Review 5.  Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology.

Authors:  Cheryl L Holmes; Donald W Landry; John T Granton
Journal:  Crit Care       Date:  2003-06-26       Impact factor: 9.097

Review 6.  Clinical review: Vasopressin and terlipressin in septic shock patients.

Authors:  Anne Delmas; Marc Leone; Sébastien Rousseau; Jacques Albanèse; Claude Martin
Journal:  Crit Care       Date:  2004-09-09       Impact factor: 9.097

7.  Vasopressin vs Terlipressin in Treatment of Refractory Shock.

Authors:  G Scarpati; O Piazza
Journal:  Transl Med UniSa       Date:  2013-01-04

Review 8.  Hypothalamic-Pituitary-Adrenal Axis Modulation of Glucocorticoids in the Cardiovascular System.

Authors:  Natalie G Burford; Natalia A Webster; Diana Cruz-Topete
Journal:  Int J Mol Sci       Date:  2017-10-16       Impact factor: 5.923

9.  AVPR1A distribution in the whole C57BL/6J mouse neonate.

Authors:  Katherine R Day; Alexis Coleman; Maria A Greenwood; Elizabeth A D Hammock
Journal:  Sci Rep       Date:  2020-09-03       Impact factor: 4.379

Review 10.  Science review: Vasopressin and the cardiovascular system part 1--receptor physiology.

Authors:  Cheryl L Holmes; Donald W Landry; John T Granton
Journal:  Crit Care       Date:  2003-06-26       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.